CARGO Therapeutics Inc. C... (CRGX)
12.14
0.96 (8.59%)
At close: Jan 15, 2025, 3:48 PM
undefined% (undefined)
| Bid | 12.11 |
| Market Cap | 559.01M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -17.59 |
| PE Ratio (ttm) | -0.69 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 12.18 |
| Volume | 203,779 |
| Avg. Volume (20D) | 230,137 |
| Open | 11.36 |
| Previous Close | 11.18 |
| Day's Range | 10.98 - 12.39 |
| 52-Week Range | 10.91 - 33.92 |
| Beta | undefined |
About CRGX
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cell...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 2023
Employees 170
Stock Exchange NASDAQ
Ticker Symbol CRGX
Website https://cargo-tx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for CRGX stock is "Buy." The 12-month stock price forecast is $32.5, which is an increase of 167.60% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
5 months ago ·
Source
+5.45%
CARGO Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
7 months ago ·
Source
CARGO Therapeutics shares are trading lower after the company announced it entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $110.0 million.
